Meropenem, a new carbapenem antibiotic

Pharmacotherapy

Volumn 17, Issue 4, 1997, Pages 644-669

  Fish, Douglas N ^a   Singletary, Tony J ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEROPENEM;

ANAEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; HYDROLYSIS; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; PSEUDOMEMBRANOUS COLITIS; RASH; VOMITING;

APPENDICITIS; BACTERIAL INFECTIONS; CLINICAL TRIALS; DRUG INTERACTIONS; DRUG RESISTANCE, MICROBIAL; HUMANS; MENINGITIS, BACTERIAL; MICROBIAL SENSITIVITY TESTS; PNEUMONIA, BACTERIAL; THIENAMYCINS;

EID: 0030753848     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (164)

1. Eng RHK, Munsif AN, Yangco BG, Smith SM, Chmel H. Seizure propensity with imipenem. Arch Intern Med 1989;149:1881-3.
2. Leo RJ, Ballow CH. Seizure activity associated with imipenem use: clinical case reports and review of the literature. Ann Pharmacother 1991;25:351-3.
3. Calandra G, Lydick E, Carrigan J, Weiss L, Guess H. Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin. Am J Med 1988;84:911-18.
4. Margaret BS, Drusano GL, Standiford HC. Emergence of resistance to carbapenem antibiotics in Pseudomonas aeruginosa. J Antimicrob Chemother 1989;24(suppl A):161-7.
5. Sanders CC, Sanders WE, Thomson KS, Iaconis JP. Meropenem activity against resistant gram-negative bacteria and interactions with beta-lactamases. J Antimicrob Chemother 1989;24(suppl A):187-96.
6. Chanal C, Sirot D, Chanal M, Cluzel M, Sirot J, Cluzel R. Comparative in-vitro activity of meropenem against clinical isolates including Enterobacteriaceae with expanded-spectrum beta-lactamases. J Antimicrob Chemother 1989;24(suppl A):133-41.
7. Edwards JR, Williams S, Nairn K. Therapeutic activity of meropenem in experimental infections. J Antimicrob Chemother 1989;24(suppl A):279-85.
8. Zeneca Pharmaceuticals. Merrem (meropenem) package insert. Wilmington, DE; July 1996.
9. Hikida M, Kawashima K, Yoshida M, et al. Inactivation of new carbapenem antibiotics by dehydropeptidase-I from porcine and human renal cortex. J Antimicrob Chemother 1992;30:129-34.
10. Wise R, Ashby JP, Andrews JM. The antibacterial activity of meropenem in combination with gentamicin or vancomycin. J Antimicrob Chemother 1989;24(suppl A):233-8.
11. Fukasawa M, Sumita Y, Harabe ET, et al. Stability of meropenem and effect of 1 beta-methyl substitution on its stability in the presence of renal dehydropeptidase I. Antimicrob Agents Chemother 1992;36:1577-9.
12. Mouton JW, van den Anker JN. Meropenem clinical pharmacokinetics. Clin Pharmacokinet 1995;28:275-86.
13. Inderlied CB, Lancero MG, Young LS. Bacteriostatic and bactericidal in-vitro activity of meropenem against clinical isolates, including Mycobacterium avium complex. J Antimicrob Chemother 1989;24(suppl A):85-99.
14. Moellering RC, Eliopoulos GM, Sentochnik DE. The carbapenems: new broad spectrum beta-lactam antibiotics. J Antimicrob Chemother 1989;24(suppl A):1-7.
15. Kitzis MD, Acar JF, Gutman L. Antibacterial activity of meropenem against gram-negative bacteria with a permeability defect and against staphylococci. J Antimicrob Chemother 1989;24(suppl A):125-32.
16. Sumita Y, Fukasawa M, Okunda T. Affinities of SM-7338 for penicillin-binding proteins and its release from these proteins in Staphylococcus aureus. Antimicrob Agents Chemother 1990;34:484-6.
17. Majcherczyk PA, Livermore DM. Penicillin-binding protein (PBP) 2 and the post-antibiotic effect of carbapenems. J Antimicrob Chemother 1990;26:593-4.
18. Sumita Y, Fukasawa M, Okuda T. Comparison of two carbapenems, SM-7338 and imipenem: affinities for penicillin-binding proteins and morphological changes. J Antibiot (Tokyo) 1990;43:314-20.
19. Edwards JR. Meropenem: a microbiological overview. J Antimicrob Chemother 1995;36(suppl A):1-17.
20. Yourassowsky L, Van der Linden MP, Lismont MJ, Crokaert F, Glpczynski Y. Bactericidal activity of meropenem against Pseudomonas aeruginosa. J Antimicrob Chemother 1989;24(suppl A):169-74.
21. Yourassowsky E, van der Linden MP, Crokaert F. Antibacterial effect of meropenem and imipenem on Proteus mirabilis. J Antimicrob Chemother 1990;26:185-92.
22. Jones RN, Barry AL, Thornsberry C. In-vitro studies of meropenem. J Antimicrob Chemother 1989;24(suppl A):9-24.
23. King A, Boothman C, Phillips I. Comparative in-vitro activity of meropenem on clinical isolates from the United Kingdom. J Antimicrob Chemother 1989;24(suppl A):31-45.
24. Clarke AM, Zemcov SJV. In-vitro activity of meropenem against clinical isolates obtained in Canada. J Antimicrob Chemother 1989;24(suppl A):47-55.
25. Kayser FH, Morenzoni G, Strassle A, Hadorn K. Activity of meropenem against gram-positive bacteria. J Antimicrob Chemother 1989;24(suppl A):101-12.
26. Nord CE, Lindmark A, Persson I. Susceptibility of anaerobic bacteria to meropenem. J Antimicrob Chemother 1989;24(suppl A):113-17.
27. Watt B, Naden M. The growth-inhibitory properties of meropenem against anaerobes of clinical importance. J Antimicrob Chemother 1989;24(suppl A):119-24.
28. Edwards JR, Turner PJ, Wannop C, Withnell ES, Grindey AJ, Nairn K. In-vitro antibacterial activity of SM-7338, a carbapenem antibiotic with stability to dihydropeptidase I. Antimicrob Agents Chemother 1989;33:215-22.
29. Sentochnik DE, Eliopoulos GM, Ferraro MJ, Moellering RC. Comparative in-vitro activity of SM-7338, a new carbapenem antimicrobial agent. Antimicrob Agents Chemother 1989;33:1232-6.
30. Neu HC, Novelli A, Chin NX. In-vitro activity and beta-lactamase stability of a new carbapenem, SM-7338. Antimicrob Agents Chemother 1989;33:1009-18.
31. Jones RN, Aldridge KE, Allen SD, et al. Multicenter in vitro evaluation of SM-7338, a new carbapenem. Antimicrob Agents Chemother 1989;33:562-5.
32. Schito GC, Sanna A, Chezzi C, et al. In-vitro activity of meropenem against clinical isolates in a multi-center study in Italy. J Antimicrob Chemother 1989;24(suppl A):57-72.
33. Bauernfeind A, Jungwirth R, Schweighart S. In-vitro activity of meropenem, the penem HRE-664 and ceftazidime against clinical isolates from West Germany. J Antimicrob Chemother 1989;24(suppl A):73-84.
34. Harabe E, Kawai Y, Kanazawa K. In vitro and in vivo antibacterial activities of meropenem, a new carbapenem antibiotic. Drugs Exp Clin Res 1992;18(2):37-46.
35. Hoban DJ, Jones RN, Yamane N, et al. In vitro activity of three carbapenem antibiotics. Comparative studies with biapenem (L-627), imipenem, and meropenem against aerobic pathogens isolated worldwide. Diagn Microbiol Infect Dis 1993;17:299-305.
36. Sader HS, Jones RN. Antimicrobial activity of the new carbapenem biapenem compared to imipenem, meropenem and other broad-spectrum beta-lactam drugs. Eur J Clin Microbiol Infect Dis 1993;12:384-91.
37. Wiedemann B, Zuhlsdorf M. Antibacterial properties of meropenem towards clinical isolates, beta-lactamase producers and laboratory mutants. J Antimicrob Chemother 1989;24(suppl A):197-205.
38. Sumita Y, Inoue M, Mitsuhashi S. In vitro antibacterial activity and beta-lactamase stability of the new carbapenem SM-7338. Eur J Clin Microbiol 1989;8:908-16.
39. Visser MR, Hoepelman IM, Beumer H, et al. Comparative in vitro antibacterial activity of the new carbapenem meropenem (SM-7338). Eur J Clin Microbiol Infect Dis 1989;8:1061-4.
40. Catchpole CR, Wise R, Thornber D. In vitro activity of L-627, a new carbapenem. Antimicrob Agents Chemother 1992;36:1928-34.
41. Wise R, Andrews JM, Ashby JP, et al. In vitro activity of a catechol-substituted cephalosporin, GR69153. Antimicrob Agents Chemother 1991;35:329-34.
42. Yeo S-F, Livermore DM. Comparative in-vitro activity of biapenem and other carbapenems against Haemophilus influenzae isolates with known resistance mechanisms to ampicillin. J Antimicrob Chemother 1994;33:861-5.
43. Jorgensen JH, Maher LA, Howell AW. Activity of a new carbapenem antibiotic, meropenem, against Haemophilus influenzae strains with beta-lactamase and non-enzyme mediated resistance to ampicillin. Antimicrob Agents Chemother 1991;35:600-2.
44. Ravizzola G, Pinsi G, Gonzales R, et al. Antibacterial activity of the new carbapenem meropenem (SM-7338) against clinical isolates. Eur J Clin Microbiol Infect Dis 1989;8:1053-61.
45. Sarubbi F, Franzus B, Verghese A. Comparative activity of meropenem (SM-7338) against major respiratory pathogens and amikacin-resistant nosocomial isolates. Eur J Clin Microbiol Infect Dis 1992;11:65-8.
46. Voutsinas D, Mavroudis T, Avlamis A, et al. In-vitro activity of meropenem, a new carbapenem, against multiresistant Pseudomonas aeruginosa compared with that of other antipseudomonal antimicrobials. J Antimicrob Chemother 1989;24(suppl A):143-7.
47. Lewin C, Doherty C, Govan J. In vitro activities of meropenem, PD 127391, PD 131628, ceftazidime, chloramphenicol, cotrimoxazole, and ciprofloxacin against Pseudomonas cepacia. Antimicrob Agents Chemother 1993;37:123-5.
48. Powell M, Seetulsingh P, Williams JD. In-vitro susceptibility of Haemophilus influenzae to meropenem compared with imipenem, five other beta-lactams, chloramphenicol and ciprofloxacin. J Antimicrob Chemother 1989;24(suppl A):175-81.
49. Jorgensen JH, Maher LA, Howell AW. Activity of meropenem against antibiotic-resistant or infrequently encountered gram-negative bacilli. Antimicrob Agents Chemother 1991;35:2410-14.
50. Linares J, Alonso T, Perez JL, et al. Decreased susceptibility of penicillin-resistant pneumococci to twenty-four beta-lactam antibiotics. J Antimicrob Chemother 1992;30:279-88.
51. Nordmann P, Ronco E. In-vitro antimicrobial susceptibility of Rhodococcus equi. J Antimicrob Chemother 1992;29:383-93.
52. Yazawa K, Mikami Y, Ohashi S, et al. In-vitro activity of new carbapenem antibiotics: comparative studies with meropenem, L-627 and imipenem against pathogenic Nocardia spp. J Antimicrob Chemother 1992;29:169-72.
53. Watt B, Naden M. The growth-inhibitory properties of meropenem against anaerobes of clinical importance. J Antimicrob Chemother 1989;24(suppl A):119-24.
54. Sheikh W, Pitkin DH, Nadler H. Antibacterial activity of meropenem and selected comparative agents against anaerobic bacteria at seven North American centers. Clin Infect Dis 1993;16(suppl 4):361-6.
55. Garcia-Rodriguez JA, Garcia SJE, Trujillano I, et al. Meropenem: in-vitro activity and kinetics against organisms of the Bacteroides fragilis group. J Antimicrob Chemother 1991;27:599-606.
56. Aldridge KE, Morice N, Schiro DD. In vitro activity of biapenem (L-627), a new carbapenem, against anaerobes. Antimicrob Agents Chemother 1994;38:889-93.
57. Murray PR, Niles AC. In vitro activity of meropenem (SM-7338), imipenem, and five other antibiotics against anaerobic clinical isolates. Diagn Microbiol Infect Dis 1990;13:57-61.
58. Appelbaum PC, Spangler SK, Jacobs MR. Susceptibilities of 394 Bacteroides fragilis, non-B. fragilis group Bacteroides species, and Fusobacterium species to newer antimicrobial agents Antimicrob Agents Chemother 1991;35:1214-18.
59. Garcia-Rodriguez JA, Garcia-Sanchez JE, Trujillano-Martin I, et al. L-627, a novel carbapenem: in-vitro activity against anaerobes. J Antimicrob Chemother 1994;33:183-6.
60. Nord CE, Lindmark A, Persson I. In vitro activity of L-627 against anaerobic bacteria. Eur J Clin Microbiol Infect Dis 1992;11:757-60.
61. Goldstein EJC, Citron DM, Cherubin CE, et al. Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole. J Antimicrob Chemother 1993;31:363-72.
62. Ferrara A, Grassi G, Grassi F, et al. Bactericidal activity of meropenem and interactions with other antibiotics. J Antimicrob Chemother 1989;24(suppl A):239-50.
63. Pfaller MA, Jones RN, Washington JA, et al. Interpretive criteria and quality control guidelines for lomefloxacin and meropenem in susceptibility tests of Haemophilus influenzae using Haemophilus test medium. Diagn Microbiol Infect Dis 1992;15:145-50.
64. Edwards JR, Turner PJ. Laboratory data which differentiate meropenem and imipenem. Scand J Infect Dis 1995;96(suppl):5-10.
65. MacGowan AP, Bowker KE, Bedford KA, Holt HA, Reeves DS, Hedges A. The comparative inhibitory and bactericidal activities of meropenem and imipenem against Acinetobacter spp and Enterobacteriaceae resistant to second generation cephalosporins. J Antimicrob Chemother 1995;35:333-7.
66. Wiseman LR, Wagstaff AJ, Brogden RN, Bryson HM. Meropenem: a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 1995;50:73-101.
67. MacKenzie FM, Gould IM, Chapman DG, et al. Comparison of methodologies used in assessing the postantibiotic effect. J Antimicrob Chemother 1994;34:223-30.
68. Nadler HL, Sheik W. A comparison of the in vitro post-antibiotic effect of meropenem and imipenem versus selected Enterobacteriaceae and other pathogens. Diagn Microbiol Infect Dis 1993;17:71-3.
69. Odenholt-Tornqvist I. Studies on the postantibiotic effect and the postantibiotic sub-MIC effect of meropenem. J Antimicrob Chemother 1993;31:881-92.
70. Nadler HL, Pitkin DH, Sheikh W. The postantibiotic effect of meropenem and imipenem against selected bacteria. J Antimicrob Chemother 1989;24(suppl A):225-31.
71. Martin CMM, Fuentes MF, Izquierdo IJ, et al. In-vivo and in vitro study of the postantibiotic effect of meropenem. J Antimicrob Chemother 1993;32:917-18.
72. MacKenzie FM, Gould IM, Chapman DG, et al. Postantibiotic effect of meropenem on members of the family Enterobacteriaceae determined by five methods. Antimicrob Agents Chemother 1994;38:2583-9.
73. Easmon CSF. Interaction of meropenem with humoral and phagocytic defenses. J Antimicrob Chemother 1989;24(suppl A):259-64.
74. Cuffini AM, Tullio V, Allocco A, et al. The entry of meropenem into human macrophages and us immunomodulating activity. J Antimicrob Chemother 1993;32:695-703.
75. Traub WH, Leonhard B, Bauer D. Intracellular bactericidal activities of cefpirome and meropenem as compared with ciprofloxacin against Serratia marcescens. Med Microbiol Lett 1994;3:173-80.
76. Cornaglia G, Guan L, Fontana R, et al. Diffusion of meropenem and imipenem through the outer membrane of Escherichia coli K-12 and correlation with their antibacterial activities. Antimicrob Agents Chemother 1992;36:1902-8.
77. Livermore DM. Mechanisms of resistance to β-lactam antibiotics. Scand J Infect Dis 1991;78(suppl):7-16.
78. Labia R, Morand A, Tiwari K, Sirot D, Chanal C. Interactions of meropenem with beta-lactamases, including enzymes with extended spectrum activity against third-generation cephalosporins. J Antimicrob Chemother 1989;24(suppl A):219-23.
79. Livermore DM. Interplay of impermeability and chromosomal beta-lactamase activity in imipenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 1992;36:2046-8.
80. Sirot D. Expanded-spectrum plasmid-mediated β-lactamases. J Antimicrob Chemother 1995;36(suppl A):19-34.
81. Zhou XY, Kitzis M-D, Gutman L. Role of cephalosporinase in carbapenem resistance of clinical isolates of Pseudomonas aeruginosa Antimicrob Agents Chemother 1993;37:1387-9.
82. Satake S, Yoneyama H, Nakae T. Role of OmpD2 and chromosomal beta-lactamase in carbapenem resistance in clinical isolates of Pseudomonas aeruginosa. J Antimicrob Chemother 1991;28:199-207.
83. Satake S, Yoshihara E, Nakae T. Diffusion of beta-lactam antibiotics through liposome membranes reconstituted from purified porins of the outer membrane of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1990;34:685-90.
84. Livermore DM, Yang Y. Comparative activity of meropenem against Pseudomonas aeruginosa strains with well-characterized resistance mechanisms. J Antimicrob Chemother 1989;24(suppl A):149-59.
85. Gotoh N, Tanaka S, Nishino T. Permeability of the outer membrane of Moraxella catarrhalis for β-lactam antibiotics. J Antimicrob Chemother 1992;29:279-85.
86. Raimondi A, Traverso A, Nikaido H. Imipenem- and meropenem-resistant mutants of Enterobacter cloacae and Proteus rettgeri lack porins. Antimicrob Agents Chemother 1991;35:1174-80.
87. Trias J, Nikaido H. Outer membrane protein D2 catalyzes facilitated diffusion of carbapenems and penems through the outer membrane of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1990;34:52-7.
88. Li X-Z, Livermore DM, Nikaido H. Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: resistance to tetracycline, chloramphenicol, and norfloxacin. Antimicrob Agents Chemother 1994;38:1732-41.
89. Nilsson-Ehle I, Hutchison M, Haworth SJ, et al. Pharmacokinetics of meropenem compared to imipenemcilastatin in young healthy males. Eur J Clin Microbiol Infect Dis 1991;10:85-8.
90. Kelly HC, Hutchison M, Haworth SJ. A comparison of the pharmacokinetics of meropenem after administration by intravenous injection over 5 min and intravenous infusion over 30 min. J Antimicrob Chemother 1995;36(suppl A):3542.
91. Bax RP, Bastain W, Featherstone A, Wilkinson DM, Huchison M, Haworth SJ. The pharmacokinetics of meropenem in volunteers. J Antimicrob Chemother 1989;24(suppl A):311-20.
92. Drusano GL, Hutchison M. The pharmacokinetics of meropenem. Scand J Infect Dis 1995;96(suppl):11-16.
93. Burman IA, Nilsson-Ehle I, Hutchison M, Haworth SJ, Norrby SR. Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem. J Antimicrob Chemother 1991;27:219-24.
94. Lyon JA. Imipenem/cilastatin: the first carbapenem antibiotic. Drug Intell Clin Pharm 1985;19:894-9.
95. Dagan R, Velghe L, Rodda JL. Penetration of meropenem into the cerebrospinal fluid of patients with inflamed meninges. J Antimicrob Chemother 1994;34:175-9.
96. Hutchison M, Faulkner KL, Turner PJ, et al. A compilation of meropenem tissue distribution data. J Antimicrob Chemother 1995;36(suppl A):43-56.
97. Newsome SWB, Palsingh J, Wells FC, Kelly HC. Penetration of meropenem into heart valve tissue. J Antimicrob Chemother 1995;36(suppl A):57-62.
98. Bergogne-Berezin E, Muller-Serieys C, Aubier M, et al. Concentration of meropenem in serum and in bronchial secretions in patients undergoing fiberoptic bronchoscopy. Eur J Clin Pharmacol 1994;46(1):87-8.
99. Hextall A, Andrews JM, Donovan IA, Wise R. Intraperitoneal penetration of meropenem. J Antimicrob Chemother 1991;27:314-15.
100. Granai F, Smart HL, Triger DR. A study of penetration of meropenem into bile using endoscopic retrograde cholangiography. J Antimicrob Chemother 1992;29:711-18.
101. Mouton JW, Michel MF. Pharmacokinetics of meropenem in serum and suction blister fluid during continuous and intermittent infusion. J Antimicrob Chemother 1991;28:911-18.
102. Wise R, Logan M, Cooper M, Ashby JP, Andrews JM. Meropenem pharmacokinetics and penetration into an inflammatory exudate. Antimicrob Agents Chemother 1990;34:1515-17.
103. Donnelly JP, Horrevorts AM, Sauerwein RW, et al. High-dose meropenem in meningitis due to Pseudomonas aeruginosa. Lancet 1992;1:1117.
104. Nairn K, Shepherd GL, Edwards JR. Efficacy of meropenem in experimental meningitis. J Antimicrob Chemother 1995;36(suppl A):73-2.
105. Harrison MP, Moss SR, Featherstone A, Fowkes AG, Sanders AM, Case DE. The disposition and metabolism of meropenem in laboratory animals and man. J Antimicrob Chemother 1989;24(suppl A):265-77.
106. 14C-meropenem in man. Xenobiotica 1993;23:1311-23.
107. Norrby SR, Alestig K, Bjornegard B, et al. Urinary recovery of N-formididoyl thienamycin (MK0787) as affected by coadministration of N-formididoyl thienamycin dehydropeptidase inhibitors. Antimicrob Agents Chemother 1983;23:300-7.
108. Norrby SR, Alestig K, Ferber F, et al. Pharmacokinetics and tolerance of N-formididoyl thienamycin (MK0787) in humans. Antimicrob Agents Chemother 1983;23:293-9.
109. Reed M, Kearns G, Jacobs R, et al. Dose ranging and pharmacokinetic evaluation of meropenem in infants and children [abstr]. Presented at the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, October 11-14, 1992.
110. Parker EM, Hutchison M, Blumer JL. The pharmacokinetics of meropenem in infants and children: a population analysis. J Antimicrob Chemother 1995;36(suppl A):63-72.
111. Leroy A, Fillastre JP, Borsa-Lebas F, et al. Pharmacokinetics of meropenem (ICI 194,660) and its metabolites (ICI 213,689) in healthy subjects and in patients with renal impairment. Antimicrob Agents Chemother 1992;36:2794-8.
112. Leroy A, Fillastre JP, Etienne I, Borsa-Lebas F, Humbert G. Pharmacokinetics of meropenem in subjects with renal insufficiency. Eur J Clin Pharmacol 1992;42:535-8.
113. Chimata M, Nagase M, Suzuki Y, et al. Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease. Antimicrob Agents Chemother 1993;37:229-33.
114. Christensson BA, Nilsson-Ehle I, Hutchison M, et al. Pharmacokinetics of meropenem in subjects with various degrees of renal impairment. Antimicrob Agents Chemother 1992;36:1532-7.
115. Ljungberg B, Nilsson-Ehle I. Pharmacokinetics of meropenem and its metabolite in young and elderly healthy men. Antimicrob Agents Chemother 1992;36:1437-40.
116. Christensson BA, Ljundberg B, Eriksson L, et al. Pharmacokinetics of meropenem in cystic fibrosis patients [abstr]. Presented at the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; Orlando, FL, October 4-7, 1994.
117. Bedikian A, Okamoto MP, Randall K, et al. Pharmacokinetics of meropenem in patients with intra-abdominal infections. Antimicrob Agents Chemother 1994;38:151-4.
118. Brismar B, Malmborg AS, Tuncrall G, et al. Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections. Report from a Swedish study group. J Antimicrob Chemother 1995;35:139-48.
119. Geroulanos SJ, and the Meropenem Study Group. Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. J Antimicrob Chemother 1995;36,(suppl A):191-205.
120. Kanellakopoulou K, Giamarellou H, Papadothomakos P, et al. Meropenem versus imipenem/cilastatin in the treatment of intraabdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis 1993;12:449-53.
121. Condon RE, Walker AP, Sirinek KR, et al. Meropenem compared to tobramycin plus clindamycin in intraabdominal infections: results of a prospective, randomized, double-blind clinical trial. Clin Infect Dis 1995;21:544-50.
122. Berne TV, Yellin AE, Appleman MD, Heseltine PNR, Gill MA. Meropenem versus tobramycin with clindamycin in the antibiotic management of patients with advanced appendicitis. J Am Coll Surg 1996;182(5):403-7.
123. Huizinga WKJ, Warren BL, Baker LW, et al. Antibiotic monotherapy with meropenem in the surgical management of intra-abdominal infections. J Antimicrob Chemother 1995;36(suppl A):179-89.
124. Colardyn F. Meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections [abstr]. Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 17-20, 1995.
125. Garau J, Blanquer J, Cobo L, et al. Meropenem versus imipenem/cilastatin in the treatment of nosocomially-acquired serious bacterial infections [abstr]. Presented at the 1st European Congress of Chemotherapy, Glasgow, Scotland, May 14-17, 1996.
126. Hartenauer U, Kljucar S, Bender H-J, Weilemann S, Nuber H, Bodmann KF. Meropenem versus imipenem/cilastatin in the treatment of severe hospital-acquired infections at ICU [abstr]. Presented at the 6th Biennial Conference on Antiinfective Agents and Chemotherapy, Leipzig, Germany, May 2-4, 1996.
127. Kempf P, Bauernfeind A, Griesenbeck K, Mannl HFK, Rueckert K, Wendling P. Meropenem-monotherapy vs cefotaxime plus metronidazole combination therapy in the treatment of serious intraabdominal infections [abstr]. Presented at the 6th Biannual Conference on Antiinfective Agents and Chemotherapy, Leipzig, Germany, May 2-4, 1996.
128. Schmutzhard E, Williams KJ, Vukmirovitis G, et al. A randomized comparison of meropenem with cefotaxime or ceftriaxone for the treatment of bacterial meningitis in adults. J Antimicrob Chemother 1995;36(suppl A):85-97.
129. Klugman KP, Dagan R, and the Meropenem Meningitis Study Group. Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Antimicrob Agents Chemother 1995;39:1140-6.
130. Feris J, Rodriguez W, Puig J, et al. Meropenem versus cefotaxime therapy for pediatric meningitis, therapeutic, pharmacologic, and epidemiologic observations [abstr]. Presented at the 35th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 17-20, 1995.
131. Bradley JS, and the Meropenem Meningitis Study Group. A multicenter study of meropenem versus cefotaxime in the therapy of pediatric meningitis [abstr]. Presented at the 95th general meeting of the American Society for Microbiology, Washington, DC, May 21-25, 1995.
132. Romanelli G, Cravarezza P, and the Italian Intramuscular Meropenem Study Group. Intramuscular meropenem in the treatment of bacterial infections of the urinary and lower respiratory tracts. J Antimicrob Chemother 1995;36(suppl A):109-19.
133. Mouton YJ, Beuscart C, and the Meropenem Study Group Empirical monotherapy with meropenem in serious bacteria infections. J Antimicrob Chemother 1995;36(suppl A):145-56.
134. Hamacher J, Vogel F, Lichey J, et al. Treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease in hospitalized patients - a comparison of meropenem and imipenem/cilastatin. J Antimicrob Chemother 1995;36(suppl A):121-33.
135. Hara K, Sakamoto A, Komori K, et al. A comparative study of meropenem and imipenem/cilastatin sodium in bacteria pneumonia [in Japanese]. Chemotherapy (Tokyo) 1992;40:1343-64.
136. Hara K, Kono S, Koga H, et al. A comparative study of meropenem and imipenem/cilastatin sodium in chronic respiratory tract infections [in Japanese]. Chemotherapy (Tokyo) 1992;40:1426-50.
137. Hara K, Kono S, Koga H, et al. Dose-finding study on meropenem in bacterial pneumonia [in Japanese]. Chemotherapy (Tokyo) 1992;40(suppl 1):447-63.
138. Sieger B, Geckler R. A comparison of meropenem and ceftazidime plus tobramycin in the treatment of hospital-acquired lower respiratory infections [abstrl. Presented at the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, October 17-20, 1993.
139. Byrne S, Maddison J, Connor P, et al. Clinical evaluation of meropenem versus ceftazidime for the treatment of Pseudomonas spp. infections in cystic fibrosis patients. J Antimicrob Chemother 1995;36(suppl A)-.135-43.
140. Solberg CO, Sjursen H. Safety and efficacy of meropenem in patients with septicaemia: a randomized comparison with ceftazidime, alone or combined with amikacin. J Antimicrob Chemother 1995;36(suppl A):157-66.
141. Cometta A, Calandra T, Gaya H, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1996;40:1108-15.
142. The Meropenem Study Group of Leuven, London and Nijmegen. Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. J Antimicrob Chemother 1995;36:185-200.
143. Behre G, Schiel X, Link H, et al. Meropenem monotherapy vs ceftazidime plus amikacin in the treatment of febrile episodes in neutropenic patients [abstr]. Onkologie 1995;18(suppl 2):196.
144. Domingo A, Zubizarreta A, Figuera A, Camara R. Meropenem versus ceftazidime plus amikacin in the treatment of febrile episodes in neutropenic patients [abstr]. Presented at the 19th International Congress of Chemotherapy, Montreal, Canada, July 16-21, 1995.
145. Shah PM, Heller A, Fuhr HG, et al. Empiric monotherapy with meropenem versus imipenem/cilastatin in the treatment of febrile episodes in neutropenic patients: a multicentre open, randomised comparative trial. Presented at the 2nd International Symposium on Febrile Neutropema, Brussels, Belgium, December 14-16, 1995.
146. Vandercam B, Jacquy C, Delaere B, et al. Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenic patients [abstr]. Presented at the 2nd International Symposium on Febrile Neutropenia, Brussels, Belgium, December 14-16, 1995.
147. Nichols RL, Smith JW, Geckler RW, et al. Meropenem versus imipenem/cilastatin in the treatment of hospitalized patients with skin and soft tissue infections. South Med J 1995;88:397-404.
148. Lami JL, Wilson SE, Hopkins JA. Adjunctive antimicrobials in surgery of soft tissue infections: evaluation of cephalosporins and carbapenems. Am Surg 1991;57:769-74.
149. Cox CE, Holloway WJ, Geckler RW. A multicenter comparative study of meropenem and imipenem/cilastatin in the treatment of complicated urinary tract infections in hospitalized patients. Clin Infect Dis 1995;21:86-92.
150. Kumazawa J, Matsumoto T, Masatoshi T, et al. Clinical evaluation of meropenem for the treatment of complicated urinary tract infections - a double-blind controlled study using imipenem/cilastatin. Nippon Hinyokika Gakkai Zasshi ?? 1992;54(6):954-69.
151. Kumazawa J, Matsumoto T, Tanaka M, et al. Dose finding study of meropenem in complicated urinary tract infection [in Japanese]. Chemotherapy (Tokyo) 1992;40(suppl 1):631-45.
152. Naber KG. Efficacy of meropenem in both complicated and uncomplicated urinary tract infection: comparison with ceftazidime [abstr]. Presented at the 8th Mediterranean Congress on Chemotherapy, Athens, Greece, May 24-29, 1992.
153. Martens M, Hemsell D. A comparison of meropenem and clindamycin-gentamicin in the treatment of obstetric and gynecologic infections [abstr]. Presented at the 33rd Interscience Conference of Antimicrobial Agents and Chemotherapy, New Orleans, LA, October 17-20, 1993.
154. Cho N, Araki H, Kimura T, et al. Basic and clinica studies of meropenem in obstetrics and gynecology [in Japanese]. Chemotherapy (Tokyo) 1992;40(suppl 1):657-68.
155. Matsuda S. Clinical study of SM-7338 in obstetrics and gynecology [in Japanese]. Chemotherapy (Tokyo) 1992;40:133.
156. Matsuda S. Pharmacokinetic and clinical studies of meropenem in the field of obstetrics and gynaecological infection [abstr]. Presented at the 8th Mediterranean Congress on Chemotherapy, Athens, Greece, May 24-29, 1992.
157. Norrby SR, Newell PA, Faulkner KL, Lesky W. Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem. J Antimicrob Chemother 1995;36(suppl A):207-23.
158. De Sarro A, Ammendola D, Zappala M, Grasso S, De Sarro GB. Relationship between structure and convulsant properties of some β-lactam antibiotics following intracerebroventricular microinjection in rats. Antimicrob Agents Chemother 1995;39:232-7.
159. Patel J, Giles RE. Meropenem: evidence of lack of proconvulsive tendency in mice. J Antimicrob Chemother 1989;24(suppl A):307-9.
160. Schliamser SE, Cars O, Norrby SR. Neurotoxicity of β-lactam antibiotics: predisposing factors and pathogenesis. J Antimicrob Chemother 1991;27:405-25.
161. Fink MP, Snydman DR, Niederman MS, et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. Antimicrob Agents Chemother 1994;38:547-57.
162. Guglielmo BJ, Jacobs RA. Impact of a dosage-monitoring system on frequency of seizures associated with imipenem-cilastatin. Am J Health-Syst Pharm 1996;53:2097-8.
163. Newcomb HW, Hill EM, McCarthy ID, Mostow SR. Imipenem-cilastatin dosing intervention program by pharmacists. Am J Hosp Pharm 1992;49:1133-5.
164. Garrett HM. Red book. Montvale, NJ: Medical Economics Company, 1996.